Novartis Business Development at a Glance

Last Modified Date: February 16, 2018

Among the top pharmaceutical companies, Novartis ranked 6th by revenue in 2017 (source). Novartis has large cash reserves as well as an impressive pipeline of pre-clinical and clinical assets. In August 2017, Novartis made headlines when the FDA approved Kymriah™ (tisagenlecleucel), the first chimeric antigen receptor T cell therapy (CAR-T). Kymriah beat out the other contenders in the race for CAR-T cancer therapies, including Kite Pharma (acquired by Gilead Sciences August 2017) and Juno Therapeutics (acquired by Celgene January 2018).

Novartis Stock

Novartis International AG
Company Type: Large Pharma
Region: Switzerland, Worldwide
Cash Position: USD 9 485M
Therapeutic Focus: Immuno-Oncology, Cardio-Metabolic, Immunology & Dermatology, Ophthalmology, Neuroscience, Respiratory


Deal Activity

Novartis Data

Figure 1. Novartis International AG. In-Licensing Deals and Acquisitions, 2013 through Present (February 2018)

Recent Deal Highlights:

EXCLUSIVE LICENSE OF FIRST OPHTHALMOLOGY GENE THERAPY LUXTURNA™ (VORETIGENE NEPARVOVEC-RZYL) FROM SPARK THERAPEUTICS

Total Size: USD 170M | Upfront: USD 105M | Therapeutic Area: Ophthalmology | Date: January 2018

PRESS

ACQUISITION OF ADVANCED ACCELERATOR APPLICATIONS SA, A NUCLEAR MEDICINES COMPANY

Total Size: USD 3 900M | Therapeutic Area: Oncology, Cardiology, Neuroscience | Date: October 2017

PRESS

COLLABORATION WITH IBM WATSON HEALTH IN BREAST CANCER

PRESS

R&D PIPELINE

Novartis Pipeline

Figure 2. Novartis International AG. Research Pipeline at Present (February 2018)

Products from Recent Deals:

IN-LICENSED PALOBIOFARMA’S ADENOSINE RECEPTOR ANTAGONIST ASSET Disease Area: Oncology | Status: Non-Small Cell Lung Cancer Phase I/II

ACQUIRED SELEXYS PHARMACEUTICALS CORPORATION’S ANTI-P-SELECTIN ANTIBODY

Disease Area: Hematology | Status: Sickle Cell Disease Phase II

PARTNERED WITH ADURO BIOTECH FOR CYCLIC DINUCLEOTIDE STING PLATFORM ASSETS

Disease Area: Oncology | Status: Solid Tumors and Lymphomas Phase I

BUSINESS DEVELOPMENT TEAM

  • CEO | Vasant (Vas) Narasimhan
  • Head Search & Evaluation, Global Business Development & Licensing | Dimitris Lizos
  • Head BD&L for Strategic Partnerships Team | Axel Maibuecher
  • Global Head of Business Development & Licensing, Immunology & Dermatology | Gerrard Terlouw
  • Director, Business Development & Licensing at Novartis Global Oncology | Mark Temples
  • Executive Director, Business Development & Licensing, Novartis Oncology | Paul Thibodeau
  • Executive Director, Business Development & Licensing | Laura Gold Ripin
  • Vice President, Pharma Head Search & Evaluation | Marcus Kalousek
  • Vice-President & Head, NPC Strategic Planning and Business Development & Licensing | John Krayacich
  • Global Head - Commercial - Strategic Partnerships | Troy Dale

Where did the data come from? The data and visualizations in this post come from the MotionHall OutMatch predictive out-licensing software.

How can I see more? Join the MotionHall platform today to access business development insights gleaned from data and predictive analytics.